Article
Oncology
Melanie Royce, Christy L. Osgood, Anup K. Amatya, Mallorie H. Fiero, C. J. George Chang, Tiffany K. Ricks, Krithika A. Shetty, Jeffrey Kraft, Junshan Qiu, Pengfei Song, Rosane Charlab, Jingyu Yu, Kathryn E. King, Anshu Rastogi, Brian Janelsins, Wendy C. Weinberg, Kathleen Clouse, Vicky Borders-Hemphill, Lindsey Brown, Candace Gomez-Broughton, Zhong Li, Thuy Thanh Nguyen, Zhihao Qiu, Anh-Thy Ly, Suyoung Chang, Tingting Gao, Chi-Ming Tu, Bellinda King-Kallimanis, William F. Pierce, Kelly Chiang, Clara Lee, Kirsten B. Goldberg, John K. Leighton, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: Margetuximab-cmkb in combination with chemotherapy was granted regular FDA approval for the treatment of HER2-positive metastatic breast cancer patients who have received two or more prior anti-HER2 regimens. The SOPHIA study demonstrated that margetuximab had a longer median progression-free survival compared to trastuzumab when both were combined with chemotherapy. Infusion-related reactions were reported as important safety signals associated with margetuximab plus chemotherapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Charles L. Vogel, Melody A. Cobleigh, Debu Tripathy, John C. Gutheil, Lyndsay N. Harris, Louis Fehrenbacher, Dennis J. Slamon, Maureen Murphy, William F. Novotny, Michael Burchmore, Steven Shak, Stanford J. Stewart, Michael Press
Summary: The purpose of this study was to evaluate the efficacy and safety of single-agent trastuzumab as first-line treatment in women with HER2-positive metastatic breast cancer. The results showed that single-agent trastuzumab had good efficacy and tolerability in the treatment of HER2-positive metastatic breast cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, Research & Experimental
Hao Ji, Lujie Yuan, Yaqun Jiang, Min Ye, Zhen Liu, Xiaotian Xia, Chunxia Qin, Dawei Jiang, Yongkang Gai, Xiaoli Lan
Summary: In this study, a CK14 targeting tracer, Tc-99m-HYNIC-Anti-CK14 mAb, was successfully constructed and showed high binding ability to CK14+ tumors, indicating its potential value in immunoSPECT imaging of basal-like breast cancer (BLBC).
MOLECULAR PHARMACEUTICS
(2022)
Article
Multidisciplinary Sciences
Edward Seung, Zhen Xing, Lan Wu, Ercole Rao, Virna Cortez-Retamozo, Beatriz Ospina, Liqing Chen, Christian Beil, Zhili Song, Bailin Zhang, Mikhail Levit, Gejing Deng, Andrew Hebert, Patrick Kirby, Aiqun Li, Emma-Jane Poulton, Rita Vicente, Audrey Garrigou, Peter Piepenhagen, Greg Ulinski, Michele Sanicola-Nadel, Dinesh S. Bangari, Huawei Qiu, Lily Pao, Dmitri Wiederschain, Ronnie Wei, Zhi-yong Yang, Gary J. Nabel
Summary: A trispecific antibody targeting HER2 and T cells can inhibit breast cancer cell proliferation by stimulating CD4 T cells, and induce tumor regression in a humanized mouse model.
Article
Oncology
Eugenia Fernandez, Luis Ubillos, Nabila Elgul, Maria Florencia Festari, Daniel Mazal, Otto Pritsch, Isabel Alonso, Eduardo Osinaga, Nora Berois
Summary: Research on the molecular mechanisms of breast cancer has led to the discovery of biomarkers like GalNAc-T13, which is associated with cancer aggressiveness and may serve as a novel biomarker. High expression of GalNAc-T13 is linked to worse patient survival rates, highlighting its potential prognostic significance in breast cancer diagnosis.
Article
Medicine, Research & Experimental
Yan Wang, Chunyan Liu, Nanyang Zhang, Xianqin Song, Yu Song, Duo Cai, Kehua Fang, Xiaotian Chang
Summary: The monoclonal anti-PADI4 antibody prepared in this study showed therapeutic effects on breast tumors by inhibiting the citrullination of fibronectin, thereby altering the tumor tissue microenvironment. The antibody treatment suppressed tumor growth, increased apoptotic cells, and decreased the expression of EMT-related genes in tumors.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Pharmacology & Pharmacy
Zhihui Dong, Zhuoshan Huang, Senlin Li, Ying Wang, Yandan Yao, Xianzhu Yang, Xiaoding Xu
Summary: Tumor microenvironment (TME) pH-responsive nanoparticles (NPs) were developed for systemic mRNA delivery to reverse trastuzumab resistance in breast cancer. These NPs, consisting of a pH-liable polymer and lipid, could efficiently deliver PTEN mRNA into tumor cells and up-regulate PTEN expression, ultimately blocking the PI3K/Akt signaling pathway and reversing trastuzumab resistance in breast cancer.
ACTA PHARMACEUTICA SINICA B
(2023)
Article
Oncology
Roberto Ruiu, Antonino Di Lorenzo, Federica Cavallo, Laura Conti
Summary: There is evidence suggesting that complete tumor eradication depends on eliminating cancer stem cells (CSCs). However, the resistant nature of CSCs makes them difficult to target. Although immunotherapy has shown success in cancer treatment, standard approaches are still commonly used for breast cancer. Therefore, it is important to understand the immunological properties of breast CSCs and evaluate whether immunotherapeutic strategies can be effective in breast cancer treatment. Possible CSC-targeting immunotherapeutic strategies should be further explored.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Ilana Schlam, Paolo Tarantino, Sara M. Tolaney
Summary: This article summarizes the resistance mechanisms to HER2-targeted treatments and discusses the potential strategies to overcome them in order to improve outcomes for breast cancer patients.
Article
Biochemistry & Molecular Biology
Lidia Avalle, Laura Raggi, Emanuele Monteleone, Aurora Savino, Daniele Viavattene, Luisa Statello, Andrea Camperi, Simona Aversano Stabile, Vincenzo Salemme, Niccolo De Marzo, Francesca Marino, Chiara Guglielmi, Andrea Lobascio, Cristina Zanini, Marco Forni, Danny Incarnato, Paola Defilippi, Salvatore Oliviero, Valeria Poli
Summary: In the tumor microenvironment, cancer cells activate Cancer Associated Fibroblasts (CAFs) to increase their secretion of soluble factors, which contribute to tumor cell proliferation, invasion, and dissemination. STAT3 and IL-6, as key factors, work together to maintain high levels of IL-6 secretion and STAT3 activation. The study demonstrated the essential role of STAT3 in the pro-tumorigenic functions of murine breast cancer CAFs, and identified a STAT3 signature enriched for genes encoding secreted proteins.
Article
Multidisciplinary Sciences
Amal Elamir, Saniha Ajith, Nour Al Sawaftah, Waad Abuwatfa, Debasmita Mukhopadhyay, Vinod Paul, Mohammad H. Al-Sayah, Nahid Awad, Ghaleb A. Husseini
Summary: Functionalizing liposomes with monoclonal antibodies, particularly anti-HER2 antibodies, can enhance targeted drug delivery to HER2 positive breast cancer cells. Low frequency ultrasound (LFUS) triggered drug release from liposomes can be further enhanced by the conjugation of Trastuzumab, increasing drug uptake and cellular toxicity in HER2+ cell lines. Combining immunoliposomes with LFUS is a promising technique to improve drug delivery efficiency and reduce cytotoxicity of antineoplastic drugs.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Binghe Xu, Qingyuan Zhang, Tao Sun, Wei Li, Yue'e Teng, Xichun Hu, Igor Bondarenko, Hryhoriy Adamchuk, Liangming Zhang, Dmytro Trukhin, Shusen Wang, Hong Zheng, Zhongsheng Tong, Yaroslav Shparyk, Qingyu Wang
Summary: HLX02, an approved biosimilar of trastuzumab, showed equivalent efficacy, safety, and immunogenicity compared with reference trastuzumab in patients with HER2-positive recurrent or metastatic breast cancer. The study concluded that HLX02 is a reliable alternative to trastuzumab for these patients.
Review
Oncology
Maria Jose Bravo, Antonio Manuel Burgos-Molina, Marilina Garcia-Aranda, Maximino Redondo, Teresa Tellez
Summary: Recent research has shown that there may be a synergistic effect between kinase inhibitors and immunotherapy in treating breast cancer. Kinase inhibitors can modify the tumor microenvironment to enhance the infiltration and activation of immune cells, leading to increased efficacy of subsequent immunotherapeutic interventions. Additionally, targeting specific kinase pathways can reverse immune evasion mechanisms employed by tumor cells, making them more susceptible to immune recognition and destruction. This dual approach has the potential to improve response rates and outcomes in breast cancer patients, especially those with kinase-disrupted subtypes.
Review
Genetics & Heredity
Mariana K. Najjar, Sara G. Manore, Angelina T. Regua, Hui-Wen Lo
Summary: HER2 overexpression is associated with poor prognosis in breast cancer, with HER2-targeted therapies, such as antibody-drug conjugates (ADCs), showing promising results in treating HER2-positive breast cancer. The development of ADCs leveraging the high specificity of HER2-targeted monoclonal antibodies with cytotoxic small molecules represents a significant advancement in the management of the disease.
Article
Medicine, Research & Experimental
Angela M. Araujo, Andrea Abaurrea, Peio Azcoaga, Joanna Lopez-Velazco, Sara Manzano, Javier Rodriguez, Ricardo Rezola, Leire Egia-Mendikute, Fatima Valdes-Mora, Juana M. Flores, Liam Jenkins, Laura Pulido, Inaki Osorio-Querejeta, Patricia Fernandez-Nogueira, Nicola Ferrari, Cristina Viera, Natalia Martin-Martin, Alexandar Tzankov, Serenella Eppenberger-Castori, Isabel Alvarez-Lopez, Ander Urruticoechea, Paloma Bragado, Nicholas Coleman, Asis Palazon, Arkaitz Carracedo, David Gallego-Ortega, Fernando Calvo, Clare M. Isacke, Maria M. Caffarel, Charles H. Lawrie
Summary: This study reveals the pivotal role of the cytokine oncostatin M (OSM) in regulating interactions between immune and nonimmune stromal cells and epithelial cancer cells. It demonstrates that the stromal OSM/OSMR axis reprograms the tumor microenvironment and plays a key role in breast cancer progression.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Review
Oncology
Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu
Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.
Article
Oncology
Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang
Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.
Article
Oncology
Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge
Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.
Article
Oncology
Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi
Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.
Article
Oncology
Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang
Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.